Intrathecal drug therapy: General considerations

Seminars in Pain Medicine

Volumn 1, Issue 4, 2003, Pages 228-233

  Przybyl, Jaroslaw S ^a   Follett, Kenneth A ^a   Caraway, David ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Center for Pain Relief   (United States)

Author keywords

Analgesia; Drug delivery systems; Intrathecal; Pain; Spasticity

Indexed keywords

ANALGESIC AGENT; BACLOFEN; MORPHINE; OPIATE;

ANALGESIA; BLEEDING; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; DRUG DELIVERY SYSTEM; DRUG SAFETY; EDEMA; EPIDURAL ABSCESS; GRANULOMA; HEADACHE; HUMAN; IMPOTENCE; INFECTION; INFECTION RISK; INFUSION PUMP; INTERMETHOD COMPARISON; LIBIDO DISORDER; LONG TERM CARE; MENINGITIS; MULTIPLE SCLEROSIS; MYELITIS; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; PRURITUS; REVIEW; SEROMA; SIDE EFFECT; SPASTICITY; SPINAL CORD DISEASE; SWEATING; TREATMENT OUTCOME; URINE RETENTION; WITHDRAWAL SYNDROME; WOUND INFECTION;

EID: 15944378175     PISSN: 15375897     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spmd.2004.02.004     Document Type: Article

References (15)

1. Onofrio BM, Yaksh TL, Arnold PG: Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc 56:516-520, 1981
2. Krames ES: Intrathecal infusional therapies for intractable pain. Minneapolis, MN, Medtronic, Inc, 1991
3. Becker WJ, Ablett DP, Harris CJ, et al: Long term treatment of intractable reflex sympathetic dystrophy with intrathecal morphine. Can J Neurol Sci 22:153-159, 1995
4. Winkelmuller M, Winkelmuller W: Long term effects of continuous intrathecal opioid treatments in chronic pain of nonmalignant etiology. J Neurosurg 85:458-467, 1996
5. Coombs DW, Saunders RL, Gaaylor MS, et al: Relief of continuous chronic pain by intraspinal narcotics infusion via an implanted reservoir. JAMA 250:2336-2239, 1983
6. Yoshida GM, Nelson RW, Capen DA, et al: Evaluation of continuous intraspinal narcotic analgesia for chronic pain from benign causes. Am J Orthop 25:693-694, 1996
7. Follett KA, Doleys DM: Selection of candidates for intrathecal drug administration to treat chronic pain: considerations in pre-implantation trials. Minneapolis, MN, Medtronic, Inc, 2002
8. Doleys DM, Olson K: Psychological assessment and intervention in implantable pain therapies. Minneapolis, MN, Medtronic, Inc, 1997
9. Bennett G, Serafini M, et al: Evidence-based review of the literature on intrathecal delivery of pain medication. J Pain Sympt Manag 20:12-36, 2000 (suppl)
10. Paice JA, Penn RD, Shott S: Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Sympt Manag 11:71-80, 1996
11. Bennett G, Burchiel K, Buchser E, et al: Clinical guidelines for intraspinal infusion: report of an expert panel. J Pain Sympt Manag 20:S37-S43, 2000 (suppl)
12. Smith TJ, Staats PS, Deer T, et al: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040-4049, 2002
13. Penn RD, Savoy SM, Corcos D, et al: Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320:1517-1521, 1989
14. Gilmartin R, Bruce D, Storrs BB, et al: Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 15:71-77, 2000
15. Follett KA, Naumann CP: A prospective study of catheter-related complications of intrathecal drug delivery systems. Pain Med 2:241, 2001